Syntaxin appoints Russell Greig chairman

pharmafile | January 19, 2011 | Appointment | Research and Development Russell Greig, appointment, research and development, syntaxin 

Oxford, UK-based biotechnology company Syntaxin has appointed Dr Russell Greig as its new chairman.

Russell has over 30 years experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations.

He spent the majority of his career at GlaxoSmithKline and immediately prior to joining Syntaxin served as president of SR One, GSK’s corporate venture group.

Advertisement

Commenting on Dr Greig’s appointment, Syntaxin chief executive Dr Melanie Lee said: “I’d like to thank Andrew Sandham, who has been chairman since the founding of Syntaxin five years ago, for his considerable contribution to the growth, development and success of the company to date.

“Syntaxin is now at a transformational stage of its development. Russell’s knowledge and experience, working with both big pharma companies and in supporting high growth emerging companies will be invaluable in maximising the potential of our innovative technology platform.”

Syntaxin, which was formed through a a spinout of intellectual property and scientists from the UK’s Health Protection Agency, is developing a new class of biopharmaceuticals that treat disease through selective inhibition of cell secretory processes.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content